RxDoctor Payments Data

Laura Johnson, NP

Family · Salt Lake City, UTNPI 1225657117

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (50.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Salix Pharmaceuticals, A Division Of Bausch Health US, LLC at 55.7% of the total. Reporting peaked in 2024 at $4,244 and has fallen 61.7% since, to $1,626 in 2025. Among family clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$9,421in general payments, 2019–2025

Across 176 payments — averaging $53.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$5K
  • AbbVie$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$339
  • E.r. Squibb & Sons, L.L.C.$335
  • Ardelyx, Inc.$321
  • Phathom Pharmaceuticals, Inc.$306
  • plus $1K from 10 others

What the payments were for

  • Consulting fees$2,80030%
  • Travel & lodging$1,87320%
  • Food & beverage$4,74750%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,421 in reported general payments places this provider in the 95th percentile of 1,460 family providers in Utah.

See all family providers in Utah

Medicare billing

Part B allowed, 2024
$24,847
Medicare patients
138
Services billed
384

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide33$35,563
Omeprazole201$4,160
Esomeprazole Magnesium42$3,009
Colestipol Hcl14$1,689
CholestyramineCholestyramine (With Sugar)20$1,315
Famotidine52$766
Lansoprazole17$598
Pantoprazole Sodium13$233
Metoclopramide Hcl27$131

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,872$35,56333 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,460 family providers in Utah.

Other family in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →